KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Twist Bioscience (TWST) EBITDA (2017 - 2025)

Twist Bioscience (TWST) has disclosed EBITDA for 6 consecutive years, with -$43.9 million as the latest value for Q3 2023.

  • On a quarterly basis, EBITDA rose 14.9% to -$43.9 million in Q3 2023 year-over-year; TTM through Sep 2023 was -$203.5 million, a 7.44% increase, with the full-year FY2025 number at -$77.8 million, up 62.7% from a year prior.
  • EBITDA was -$43.9 million for Q3 2023 at Twist Bioscience, up from -$58.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$24.4 million in Q3 2020 to a low of -$61.5 million in Q1 2022.
  • A 5-year average of -$42.1 million and a median of -$41.1 million in 2021 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: plummeted 360.92% in 2019, then skyrocketed 40.96% in 2020.
  • Twist Bioscience's EBITDA stood at -$55.6 million in 2019, then surged by 40.96% to -$32.8 million in 2020, then plummeted by 38.16% to -$45.4 million in 2021, then grew by 5.12% to -$43.1 million in 2022, then dropped by 1.95% to -$43.9 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's EBITDA are -$43.9 million (Q3 2023), -$58.1 million (Q2 2023), and -$58.4 million (Q1 2023).